AI Article Synopsis
- Gastric and gastro-oesophageal junction cancers pose significant global health challenges, with poor patient prognosis despite advances in chemotherapy and surgery.
- In treating advanced disease, only certain targeted therapies like trastuzumab and immune checkpoint inhibitors such as nivolumab and pembrolizumab show consistent effectiveness, particularly in specific tumor types (HER2-positive and PD-L1-positive).
- The review examines the molecular and clinical characteristics of these cancers, discusses ongoing clinical trials on targeted agents and immunotherapy, and proposes new strategies for enhancing precision medicine to improve patient outcomes.
Article Abstract
Gastric cancer and gastro-oesophageal junction cancer represent a global health-care challenge. Despite the efficacy of improved chemotherapy and surgical options, these patients still have a poor prognosis. In advanced disease, only trastuzumab and some immune checkpoint inhibitors, such as nivolumab and pembrolizumab in addition to chemotherapy, have demonstrated consistent and reliable efficacy in patients with HER2-positive and PDL1-positive tumours, respectively. In this Review, we discuss the intrinsic characteristics of gastric and gastro-oesophageal cancer from the molecular and clinical perspectives and provide a comprehensive review of previously reported and ongoing phase II and III clinical trials with targeted agents and immunotherapy in advanced and localized settings. Finally, we suggest alternative strategies to help overcome current challenges in precision medicine and to improve outcomes for these patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41575-022-00703-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!